Dr. Nachiket Kashikar is the Head of Business Development and Commercial Operations at Apollo Life Sciences GmbH (a spin-out of QIAGEN). Apollo is located in Monheim near Düsseldorf in Germany. Apollo aims at democratizing in situ multiplexed quantification of mRNAs through its fully automated instrument platform - that offers high sensitivity and subcellular resolution in an intact tissue.
Born and raised in India (about 80 km south of Mumbai), Nachiket moved to Forschungszentrum Jülich (Germany) in 2005 for his PhD. During his PhD, Nachiket studied the biophysical mechanisms underlying sperm chemotaxis. To perform this research, he spent five summers at the Marine Biological Laboratory in Woods Hole, USA. Thereafter, he switched his focus to Neuroscience and had post-doctoral stints at the Max Planck Institute for Biophysical Chemistry in Göttingen, Medical Research Council Laboratory of Molecular Biology in Cambridge, UK and at the University of Sussex. Following that he moved to Janssen Pharmaceutica in Belgium as a Senior Scientist. At Janssen, he established a new technology platform to assay synaptic function using genetically-encoded fluorescent reporters. The platform was used to understand deficits in synaptic function in Alzheimer's disease and to perform high-throughput phenotypic drug screening. Dr. Kashikar is a recipient of Marie Curie post-doctoral fellowship and J&J Vice Presidents' Research Award for Outstanding Technical Achievement for the year 2017. He is currently pursuing Executive MBA at Solvay Brussels School of Economics Management (Belgium).